Getinge AB (publ) (STO:GETI.B)
Sweden flag Sweden · Delayed Price · Currency is SEK
230.30
+1.20 (0.52%)
Jul 24, 2026, 5:29 PM CET

Revenue Breakdown

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Acute Care Therapies Revenue
17.98B18.68B17.95B
Life Science Revenue
4.53B4.50B4.55B
Surgical Workflows Revenue
11.72B11.80B12.26B
Revenue (Other)
2.00M-1.00M
Revenue (Total)
34.24B34.97B34.76B

Revenue by Geography

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Americas Revenue
15.12B15.69B15.52B
APAC Revenue
6.59B6.94B7.06B
EMEA Revenue
12.53B12.34B12.18B
Revenue (Total)
34.24B34.97B34.76B

Revenue Breakdown 2

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Capital Goods Revenue
11.43B11.97B12.42B
Product Sales Recurring Revenue
16.01B16.19B15.59B
Service Assignments Incl. Spare Parts Recurring Revenue
6.79B6.82B6.75B
Total Recurring Revenue
22.80B23.00B22.34B
Revenue (Total)
34.24B34.97B34.76B

Gross Profit

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Acute Care Therapies Gross Profit
10.32B10.42B9.62B
Life Science Gross Profit
1.58B1.56B1.70B
Surgical Workflows Gross Profit
4.75B4.68B4.84B
Gross Profit (Other)
-3.00M-1.00M-
Gross Profit (Total)
16.64B16.65B16.15B

EBIT

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Acute Care Therapies Operating Profit
3.36B3.02B2.07B
Life Science Operating Profit
546.00M470.00M526.00M
Surgical Workflows Operating Profit
893.00M773.00M703.00M
Group Functions and Other Items Operating Profit
-486.00M-474.00M-440.00M
Operating Income (Other)
-1.00M-1.00M-
Operating Income (Total)
4.31B3.79B2.85B

Adjusted EBITDA

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Acute Care Therapies Adjusted EBITA
3.87B3.76B3.55B
Life Science Revenue Adjusted EBITA
555.00M490.00M608.00M
Surgical Workflows Adjusted EBITA
1.20B1.08B1.09B
Group Functions and Other Items Adjusted EBITA
-434.00M-450.00M-383.00M
Operating Income (Other)
-874.00M-1.09B-2.02B
Operating Income (Total)
4.31B3.79B2.85B

Key Performance Indicators

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Acute Care Therapies - Order Intake
17.66B18.22B17.72B
Life Science - Order Intake
4.37B4.25B4.60B
Surgical Workflows - Order Intake
11.61B11.55B11.91B
Total Order Intake
33.64B34.03B34.23B
Order Intake - Organic Growth
-3.50%6.30%
Acute Care Therapies Net Sales - Organic Growth
-7.00%8.20%
Life Science Net Sales - Organic Growth
-4.10%-1.90%
Surgical Workflows Net Sales - Organic Growth
-2.10%2.60%
Total Net Sales Organic Growth
-4.90%4.90%